ArticleEJNMMI research2022
Bone marrow impairment during early [
Article in EJNMMI research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Virtual-patient nonlinear mixed-effects modelling for data-driven optimisation of single-time-point dosimetry: a proof-of-concept study in [EJNMMI physics · 2026Article
- Tumor microenvironment-mediated hematologic toxicity ofWorld journal of urology · 2026Review
- The emerging role of prostate-specific membrane antigen-targeted radioligand therapy in metastatic hormone-sensitive prostate cancer.The oncologist · 2026Review
- Acute complications of nuclear medicine: an emergency medicine perspective.EJNMMI research · 2026Review
- Safety and efficacy of [European journal of nuclear medicine and molecular imaging · 2026Article
- Effect of bone marrow disease on hematologic toxicity and response to [European journal of nuclear medicine and molecular imaging · 2026Article
- Current and future perspectives on radioligand therapy in advanced prostate cancer.Therapeutic advances in medical oncology · 2026Review
- Impact of baselineEuropean journal of nuclear medicine and molecular imaging · 2025Article
- [European journal of nuclear medicine and molecular imaging · 2025Article
- Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer.Nuclear medicine and molecular imaging · 2025Review
- EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed doses.European journal of nuclear medicine and molecular imaging · 2025Review
- Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects duringTheranostics · 2025Review
- A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?EJNMMI physics · 2024Review
- Short-Term Biological Toxicity Prediction of [Cancer biotherapy & radiopharmaceuticals · 2024Observational
- Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence.European journal of nuclear medicine and molecular imaging · 2024Article
- Recent advances and applications of peptide-agent conjugates for targeting tumor cells.Journal of cancer research and clinical oncology · 2023Review
- Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors UsingPharmaceutics · 2023Article
- Extended therapy with [European journal of nuclear medicine and molecular imaging · 2023Article
- Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?Acta pharmaceutica Sinica. B · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recent phase III VISION-trial confirms the treatment efficacy of radioligand therapy with [
methodsIn this retrospective analysis, haematological parameters (HP) of 64 patients with mCRPC were systematically acquired over two cycles (12-16 weeks) of PSMA-RLT from baseline to restaging. Changes in HP were analysed qualitatively (CTCAE 5.0) and quantitatively. The HP changes from baseline were compared to quantitative and qualitative biochemical and imaging response, using PCWG3 and PROMISE criteria.
resultsAll grade 3/4 hAE observed were associated with disseminated or diffuse bone involvement as well as biochemical non-response at restaging. Quantitatively, at baseline, HP inversely correlated with biochemical and volumetric (on PET) tumour burden as well as bone involvement pattern (p ≤ 0.043). Among patients with disseminated or diffuse bone involvement, percentage changes in HP (%HP) at restaging inversely correlated with serological and imaging tumour burden (p ≤ 0.017). Biochemical non-responders showed a significant decrease in %HP (p ≤ 0.001) while HP in biochemical responders remained stable (p ≥ 0.079).
conclusionDuring early cycles of PSMA-RLT, qualitative and quantitative bone marrow impairment appears to be closely associated with osseous tumour burden as only patients with advanced bone involvement and non-response to therapy exhibited high-grade haematological adverse events, showing a significant decline of haematological parameters. This implies that in patients with advanced mCRPC, non-response to PSMA-RLT may be a major cause of bone marrow impairment during early treatment cycles. German Clinical Trial Register DRKS00013665. Registered 28 December 2017, retrospectively registered ( www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00013665 ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.